A. DeMichele

1.7k citations
39 papers · 201 · h-index 8

Impact in

  • Cancer Research
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis
    • Cancer Treatment and Pharmacology
    • Cancer-related Molecular Pathways

Papers in

  • Oncology 29
    • Cancer Treatment and Pharmacology 9
    • HER2/EGFR in Cancer Research 4
    • Cancer-related Molecular Pathways 3
    • Cancer Cells and Metastasis 3
    • Colorectal Cancer Treatments and Studies 3
  • Pulmonary and Respiratory Medicine 16
    • Advanced Breast Cancer Therapies 14
Co-authors
Philip Samuels (2 shared papers)Laura van ‘t Veer (4 shared papers)LA Carey (4 shared papers)Maggie C.U. Cheang (3 shared papers)Charles H. Graham (1 shared paper)Laura J. Esserman (3 shared papers)Kathleen Conway (3 shared papers)DB Cines (2 shared papers)
Journals
Journal of Clinical Oncology (15 papers)Cancer Research (12 papers)Annals of Oncology (3 papers)Blood (2 papers)ESMO Open (2 papers)
Partner nations
United StatesItalyAustralia

In The Last Decade

A. DeMichele

36 papers receiving 190 citations

Peers

A. DeMichele
Comparison fields: 5 of 40
  • Cancer Research 83
  • Oncology 101
  • Rheumatology 26
  • Obstetrics and Gynecology 11
  • Hematology 15
Replace Reham Hammad with:
Reham Hammad Egypt
Weiguo Sui China
Jian-ying Ma China
Valentina Gallá Italy
Ahmed Kamel Egypt
M. H. Le United States
Chang Zeng United States
Laura Matteucci Italy
Aaron G. Margulies United States
Laura Iezzi Italy
A. DeMichele relative to Reham Hammad Egypt Reham Hammad's profile →
Citations per field
00.5×2×2.9×
Reham Hammad · 1×
Citations per year

Countries citing papers authored by A. DeMichele

Since Specialization
Citations

This map shows the geographic impact of A. DeMichele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. DeMichele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. DeMichele more than expected).

Fields of papers citing papers by A. DeMichele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. DeMichele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. DeMichele. The network helps show where A. DeMichele may publish in the future.

Co-authors

The 25 scholars most cited alongside A. DeMichele, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. DeMichele Line = papers co-authored together A. DeMichele links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss
Blood ·KR McCrae, A. DeMichele, P. N. Pandhi, MJ Balsai, Philip Samuels, Charles H. Graham, PK Lala, DB Cines
199338
2
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
Journal of Clinical Oncology ·Laura J. Esserman, CM Perou, Maggie C.U. Cheang, A. DeMichele, LA Carey, Laura van ‘t Veer, J. Gray, Emanuel F. Petricoin, Kathleen Conway, D. A. Berry
200930
3
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
Journal of Clinical Oncology ·Laura J. Esserman, C. Perou, Maggie C.U. Cheang, A. DeMichele, LA Carey, Laura van ‘t Veer, J. Gray, Emanuel Petricoin, Kathleen Conway, N. Hylton, D. A. Berry
200915
4
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
Journal of Clinical Oncology ·Peter J. O’Dwyer, Patricia LoRusso, A. DeMichele, Vijay Gupta, A. Barbi, H. Dials, I. Chen, Ronan Courtney, Keith D. Wilner, Gary K. Schwartz
200714
5
HER2DX genomic test in early-stage HER2-positive breast cancer
ESMO Open ·Sara M. Tolaney, Nadine Tung, Antonio C. Wolff, A. DeMichele, J.M. Cejalvo, O. Martínez-Sáez, Tomás Pascual, A.G. Waks, Miguel Martín, Eva Ciruelos, Nadia Harbeck, Lisa A. Carey, Javier Cortés, Giuseppe Curigliano, Aleix Prat
202410
6
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)
European Journal of Cancer ·Funda Meric‐Bernstam, Nizar M. Tannir, James J. Harding, M.J. Voss, J W Mier, A. DeMichele, Pamela N. Münster, Manubhai Patel, Othon Iliopoulos, T. K. Owonikoko, Sam H. Whiting, Keith Orford, Mark K. Bennett, Richard D. Carvajal, Renée M. McKay, Alice C. Fan, Melinda L. Telli, J. Infante
20169
7
Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial
Cancer Research ·Costanza Paoletti, MM Regan, MC Liu, P. Kelly Marcom, L. Hart, J. Smith, KL Tedesco, Eitan Amir, IE Krop, A. DeMichele, PJ Goodwin, M Block, KoKo Aung, EM Cannell, EP Darga, PJ Baratta, ME Brown, R J McCormack, DF Hayes
20178
8
Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer
Cancer Research ·EL Mayer, SA Wander, MM Regan, A. DeMichele, Andres Forero, MF Rimawi, CX Ma, M Cristofanilli, CK Anders, C Huang Bartlett, María Koehler, EP Winer, HJ Burstein
20188
9
532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
European Journal of Cancer ·Annuska M. Glas, Janneke G. C. Peeters, C Yau, Denise M. Wolf, Ashish Sanil, Y. Li, Tessa Severson, Shai Linn, Meredith Buxton, A. DeMichele, Nola M. Hylton, F. Symmans, Douglas Yee, Marco Paoloni, L. Esserman, Don Berry, H. S. Rugo, OF Olopade, Laura van ‘t Veer
20147
10
Abstract OT2-07-09: Detection and targeting of minimal residual disease in breast cancer to reduce recurrence: The PENN-SURMOUNT and CLEVER trials
Cancer Research ·LJ Bayne, Isoris Nivar, Brooke Goodspeed, Paul Wileyto, Jason E. Savage, NNC Shih, MD Feldman, John Edwards, AS Clark, Kenneth R Fox, J Matro, S. Domchek, AR Bradbury, PD Shah, EM Chislock, GK Belka, J Wang, Ravi K. Amaravadi, LA Chodosh, A. DeMichele
20186
11
Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).
Journal of Clinical Oncology ·Andrew J. Rech, Rosemarie Mick, A. Recio, A. DeMichele, Carol Tweed, Kevin R. Fox, S. M. Domchek, Robert H. Vonderheide
20106
12
Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss
Blood ·KR McCrae, A. DeMichele, P. N. Pandhi, MJ Balsai, Philip Samuels, C. D. Graham, PK Lala, DB Cines
19934
13
Relationships between clinical and biochemical predictors of chemotherapy-related amenorrhea in premenopausal adjuvant breast cancer patients
Journal of Clinical Oncology ·I. Su, John Alton, L. Sherman, Corrie A. Stankiewicz, Sarah J. Ratcliffe, A. DeMichele
20074
14
Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Cancer Research ·DM Wolf, Christopher Yau, Ashish Sanil, Annuska M. Glas, Chip Petricoin, Julia Wulfkuhle, Lamorna Brown Swigart, Gillian L. Hirst, (unknown), MB Buxton, A. DeMichele, Nola M. Hylton, F Symmans, Douglas Yee, Marco Paoloni, L. Esserman, Don Berry, H. S. Rugo, Olufunmilayo I. Olapade, L. van 't Veer
20173
15
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
Breast Diseases A Year Book Quarterly ·A. DeMichele
20123
16
Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors.
Journal of Clinical Oncology ·Carrie Tompkins Stricker, Steven C. Palmer, A. DeMichele, Jun J. Mao
20103
17
Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor
Cancer Research ·Anand Bardia, SA Hurvitz, DA Yardley, Amelia Zelnak, A. DeMichele, AS Clark, Ghulam Warsi, TN Small, Chiara Di Tucci, SL Moulder
20172
18
Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
Cancer Research ·Sunil Verma, A. DeMichele, Sherene Loi, Jungsil Ro, Marco Colleoni, Hiroji Iwata, Nadia Harbeck, Vered Stearns, Massimo Cristofanilli, C Huang Bartlett, Patrick Schnell, Kai Zhang, Alexandra Thiele, Nicholas C. Turner, HS Rugo
20162
19
250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
Annals of Oncology ·Jianqin Lu, G. T. Budd, Sophia Frentzas, H. Park, Catherine Shannon, H. S. Rugo, Joyce O’Shaughnessy, A. DeMichele, Sara M. Tolaney, R.W. Eek, Amelia McCartney, Katharine Cuff, LJ Esserman, Alex Alika, Desiree H. Xu, M. Li, Tiep Le, Darryl Z. L’Heureux, Jiarui Yan, S.A. Hurvitz
20222
20
169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis
Annals of Oncology ·H. S. Rugo, Adam Brufsky, X. Liu, B. Li, Lynn McRoy, C. Chen, R.M. Layman, M. Cristofanilli, M. Torres, Giuseppe Curigliano, RS Finn, A. DeMichele
20222

About A. DeMichele

A. DeMichele is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 39 papers that have together received 201 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (14 papers), Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers), Cancer Genomics and Diagnostics (6 papers), HER2/EGFR in Cancer Research (4 papers), Cancer-related Molecular Pathways (3 papers), Cancer Cells and Metastasis (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Cancer Research (83 citations), Oncology (101 citations), Rheumatology (26 citations), Obstetrics and Gynecology (11 citations) and Hematology (15 citations). A. DeMichele has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Philip Samuels, Laura van ‘t Veer, LA Carey, Maggie C.U. Cheang, Charles H. Graham, Laura J. Esserman, Kathleen Conway, DB Cines, D. A. Berry and J. Gray. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Blood and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reham HammadBreakdown of academic impact, for papers by Weiguo SuiBreakdown of academic impact, for papers by Jian-ying MaBreakdown of academic impact, for papers by Valentina GalláBreakdown of academic impact, for papers by Ahmed KamelBreakdown of academic impact, for papers by M. H. LeBreakdown of academic impact, for papers by Chang ZengBreakdown of academic impact, for papers by Laura MatteucciBreakdown of academic impact, for papers by Aaron G. MarguliesBreakdown of academic impact, for papers by Laura Iezzi